Veteran medical device executive brings more than 35 years of commercialization, market development, and surgical technology leadership as RevMedica advances toward commercialization of its surgical stapling platform.
MIDDLETOWN, CT: RevMedica, a pioneering MedTech company set to revolutionize the way surgeons approach soft-tissue management, announces the appointment of Ronald (Ron) Galovich to its Board of Directors.
Ron joins RevMedica at an important stage in the company’s growth as it prepares for the anticipated FDA submission of its flagship powered surgical stapling platform and continues building its commercialization strategy.
With more than 35 years of medical device and life sciences experience, Ron brings extensive expertise in advancing surgical technologies from concept through commercialization, building high-performing global organizations, developing new markets, and scaling emerging medical technology companies.
“Ron has a broad surgical technology commercial experience,” said Tom Wenchell, CEO and Co-Founder, RevMedica. “His background in surgical stapling and scaling disruptive technologies is particularly valuable as RevMedica prepares for its next stage of growth. He has already become an important contributor to our go-to-market planning and commercial strategy.”
Ron has held executive and general management positions with leading medical technology companies including Covidien, Ethicon, Convatec, STERIS, and Baxter, where he led the development, launch, and commercialization of innovative and transformational technologies across the globe.
His experience is particularly relevant to RevMedica’s focus on advancing surgical stapling.
As Chief Commercial Officer of Standard Bariatrics, Inc., Ron led commercialization, market development, and scale-up activities for the company’s revolutionary bariatric stapling technology. During his tenure, the company achieved significant growth in market value, culminating in its acquisition by Teleflex Incorporated.
Most recently, Ron served as Vice President of Sales and Marketing at GT Metabolic Solutions, where he led the North American commercialization of the company’s transformational magnetic compression anastomosis technology.
“I’m honored to join the Board and work alongside such a talented and dedicated group of individuals,” said Ron. “The opportunity to help guide the development of this innovative tissue-sensing technology is extremely exciting, particularly given its potential to enhance surgical decision-making and improve patient outcomes.”
Ron holds a Bachelor of Science degree in Economics and Marketing from Indiana University of Pennsylvania and is a graduate of Columbia University’s Senior Executive Program.
About RevMedica
RevMedica is a pioneering MedTech company set to revolutionize the way surgeons approach soft-tissue management. With a mission focused on optimizing clinical decision-making and elevating patient safety, RevMedica aims to achieve these objectives through the development of cost-effective, environmentally friendly surgical systems. The seasoned RevMedica team is passionate about delivering enabling technology, better clinical results, and striving for a more sustainable operating room environment. For more information about RevMedica, visit revmedica.com.
Media Contact
Steve Lampkin
Chief Commercial Officer
RevMedica, Inc.
SteveL@revmedica.com
